JP2004501650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004501650A5 JP2004501650A5 JP2002506221A JP2002506221A JP2004501650A5 JP 2004501650 A5 JP2004501650 A5 JP 2004501650A5 JP 2002506221 A JP2002506221 A JP 2002506221A JP 2002506221 A JP2002506221 A JP 2002506221A JP 2004501650 A5 JP2004501650 A5 JP 2004501650A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- vector according
- region
- adenovirus vector
- genome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000701161 unidentified adenovirus Species 0.000 description 80
- 239000013598 vector Substances 0.000 description 48
- 102100040247 Tumor necrosis factor Human genes 0.000 description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 150000007523 nucleic acids Chemical group 0.000 description 12
- 125000006850 spacer group Chemical group 0.000 description 11
- 125000000539 amino acid group Chemical group 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 101710145505 Fiber protein Proteins 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101100444898 Mus musculus Egr1 gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/604,694 US6579522B1 (en) | 2000-06-27 | 2000-06-27 | Replication deficient adenoviral TNF vector |
| PCT/US2001/020536 WO2002000906A2 (en) | 2000-06-27 | 2001-06-27 | Replication deficient adenoviral tnf vector |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012022529A Division JP2012139220A (ja) | 2000-06-27 | 2012-02-03 | 複製欠損アデノウイルスｔｎｆベクター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004501650A JP2004501650A (ja) | 2004-01-22 |
| JP2004501650A5 true JP2004501650A5 (enExample) | 2008-07-31 |
Family
ID=24420637
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002506221A Pending JP2004501650A (ja) | 2000-06-27 | 2001-06-27 | 複製欠損アデノウイルスｔｎｆベクター |
| JP2012022529A Pending JP2012139220A (ja) | 2000-06-27 | 2012-02-03 | 複製欠損アデノウイルスｔｎｆベクター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012022529A Pending JP2012139220A (ja) | 2000-06-27 | 2012-02-03 | 複製欠損アデノウイルスｔｎｆベクター |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6579522B1 (enExample) |
| EP (1) | EP1294918B1 (enExample) |
| JP (2) | JP2004501650A (enExample) |
| AT (1) | ATE306555T1 (enExample) |
| AU (2) | AU2001271549B2 (enExample) |
| CA (1) | CA2412637A1 (enExample) |
| DE (1) | DE60114006T2 (enExample) |
| WO (1) | WO2002000906A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1180159B1 (en) * | 1999-05-28 | 2008-09-03 | Targeted Genetics Corporation | Methods and compositions for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders |
| US6579522B1 (en) * | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
| US20030086903A1 (en) | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
| US6845929B2 (en) * | 2002-03-22 | 2005-01-25 | Ali Dolatabadi | High efficiency nozzle for thermal spray of high quality, low oxide content coatings |
| US20030223962A1 (en) * | 2002-06-03 | 2003-12-04 | Cornell Research Foundation, Inc. | Delivery of gene products to the lung parenchyma via gene transfer to the pleura |
| EP2168603A1 (en) | 2003-11-14 | 2010-03-31 | GenVec, Inc. | Therapeutic regimen for treating cancer |
| NZ546983A (en) * | 2003-11-24 | 2009-05-31 | Canji Inc | Reduction of dermal scarring |
| JP2008511336A (ja) * | 2004-09-01 | 2008-04-17 | アメリカ合衆国 | 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法 |
| EP2386564B1 (en) * | 2005-10-01 | 2014-07-16 | Charles Stout | Regulatable fusion promoters |
| WO2008112540A2 (en) * | 2007-03-09 | 2008-09-18 | Vectorlogics, Inc. | Cells for adenovirus vector and protein production |
| US9605844B2 (en) * | 2009-09-01 | 2017-03-28 | Cree, Inc. | Lighting device with heat dissipation elements |
| WO2011054811A1 (en) | 2009-11-03 | 2011-05-12 | Santaris Pharma A/S | Rna antagonists targeting hsp27 combination therapy |
| US9458473B2 (en) | 2010-06-29 | 2016-10-04 | The Johns Hopkins University | Compositions and methods for retargeting virus constructs |
| KR101429696B1 (ko) * | 2012-11-21 | 2014-08-13 | 국립암센터 | 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도 |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| PL3198009T3 (pl) | 2014-09-24 | 2022-01-24 | Salk Institute For Biological Studies | Onkolityczne wirusy nowotworowe i sposoby zastosowania |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| JP7430395B2 (ja) | 2018-04-09 | 2024-02-13 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 複製特質が増強された腫瘍溶解性アデノウイルス組成物 |
| WO2024233783A1 (en) | 2023-05-09 | 2024-11-14 | Cornell University | Expression cassette coding for vascular endothelial growth factor |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US4879226A (en) | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
| US5763209A (en) | 1988-09-26 | 1998-06-09 | Arch Development Corporation | Methods and materials relating to the functional domains of DNA binding proteins |
| US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
| JP3443119B2 (ja) * | 1989-08-07 | 2003-09-02 | ペプテック リミテッド | 腫瘍壊死因子結合リガンド |
| CA2055168A1 (en) | 1990-11-21 | 1992-05-22 | Walter Fiers | Tnf-muteins |
| DK0563278T3 (da) | 1990-12-20 | 2000-08-21 | Dana Farber Cancer Inst Inc | Regulering af geneekspression med ioniserende stråling |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| US5968735A (en) | 1992-11-12 | 1999-10-19 | Max Delbruck-Centrum Fur Molekular Medizin Berlin | Vector for the expression of therapy-relevant genes |
| FR2709309B1 (fr) | 1993-08-25 | 1995-11-10 | Centre Nat Rech Scient | Compositions cellulaires, préparation et utilisations thérapeutiques. |
| US5641755A (en) | 1994-02-04 | 1997-06-24 | Arch Development Corp. | Regulation of x-ray mediated gene expression |
| US5571797A (en) | 1994-05-11 | 1996-11-05 | Arch Development Corporation | Method of inducing gene expression by ionizing radiation |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| CA2192442C (en) | 1994-06-10 | 2007-09-25 | Imre Kovesdi | Complementary adenoviral vector systems and cell lines |
| US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
| US5962424A (en) | 1995-02-21 | 1999-10-05 | Arch Development Corporation | Methods and compositions for targeting selectins |
| WO1996027021A1 (en) | 1995-03-01 | 1996-09-06 | Cornell Research Foundation, Inc. | Interdependent adenoviral vectors and methods of using same |
| WO1996033746A1 (en) | 1995-04-28 | 1996-10-31 | Genetic Therapy, Inc. | Treatment of tumors with cells expressing interferons, tumor necrosis factors, or other cytokines |
| US6281010B1 (en) * | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
| JPH11513390A (ja) * | 1995-10-06 | 1999-11-16 | アーチ デベロップメント コーポレイション | 細胞殺傷のウイルス増強のための方法および組成物 |
| JP3420586B2 (ja) | 1995-11-28 | 2003-06-23 | ジェンベク、インコーポレイティッド | 細胞への遣伝子導入のためのベクターおよび方法 |
| JP2002512501A (ja) | 1996-07-03 | 2002-04-23 | メリアル インコーポレイテッド | 外来性ｄｎａを含む組換えイヌアデノウィルス（ｃａｖ） |
| CA2232743A1 (en) | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
| US5981275A (en) | 1997-04-14 | 1999-11-09 | Genzyme Corporation | Transgene expression system for increased persistence |
| US6100086A (en) | 1997-04-14 | 2000-08-08 | Genzyme Corporation | Transgene expression systems |
| IL120979A0 (en) | 1997-06-02 | 1997-11-20 | Interpharm Lab Ltd | Glycosylated TNF |
| US6171787B1 (en) | 1997-06-26 | 2001-01-09 | Abbott Laboratories | Member of the TNF family useful for treatment and diagnosis of disease |
| AU750803B2 (en) | 1997-10-29 | 2002-07-25 | University Of Pittsburgh | Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies |
| DE19747718A1 (de) | 1997-10-29 | 1999-05-06 | Baltzer Axel Wilhelm August Dr | Verfahren zur Therapie knochenresorbierender Erkrankungen mit der molekularbiologischen Methode der Gentherapie |
| AU1377299A (en) | 1997-11-03 | 1999-05-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona, The | Hyperthermic inducible expression vectors for gene therapy and methods of use thereof |
| WO1999046371A2 (en) | 1998-03-11 | 1999-09-16 | Board Of Regents, The University Of Texas System | Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery |
| JP2002506651A (ja) | 1998-03-16 | 2002-03-05 | イントロジェン・セラピューティクス，インコーポレイテッド | 多重遺伝子ベクター |
| AU772963B2 (en) | 1998-04-24 | 2004-05-13 | Onyx Pharmaceuticals | Adenoviral vectors for treating disease |
| JP2002518341A (ja) | 1998-06-15 | 2002-06-25 | アーチ・デヴェロップメント・コーポレイション | 放射線療法と抗血管形成因子の組み合わせ |
| US6337338B1 (en) * | 1998-12-15 | 2002-01-08 | Telik, Inc. | Heteroaryl-aryl ureas as IGF-1 receptor antagonists |
| US6579522B1 (en) * | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
| US20030086903A1 (en) * | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
-
2000
- 2000-06-27 US US09/604,694 patent/US6579522B1/en not_active Expired - Fee Related
-
2001
- 2001-06-27 AU AU2001271549A patent/AU2001271549B2/en not_active Ceased
- 2001-06-27 AU AU7154901A patent/AU7154901A/xx active Pending
- 2001-06-27 DE DE60114006T patent/DE60114006T2/de not_active Expired - Lifetime
- 2001-06-27 CA CA002412637A patent/CA2412637A1/en not_active Abandoned
- 2001-06-27 JP JP2002506221A patent/JP2004501650A/ja active Pending
- 2001-06-27 EP EP01950575A patent/EP1294918B1/en not_active Expired - Lifetime
- 2001-06-27 WO PCT/US2001/020536 patent/WO2002000906A2/en not_active Ceased
- 2001-06-27 AT AT01950575T patent/ATE306555T1/de not_active IP Right Cessation
-
2003
- 2003-04-25 US US10/424,638 patent/US20030175245A1/en not_active Abandoned
-
2012
- 2012-02-03 JP JP2012022529A patent/JP2012139220A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69429260T3 (de) | Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie | |
| JP2023512519A5 (enExample) | ||
| Matsushita et al. | Adeno-associated virus vectors can be efficiently produced without helper virus | |
| JP2005505286A5 (enExample) | ||
| JP2003530307A5 (enExample) | ||
| JP2002516568A (ja) | α−フェトタンパク質を発現する細胞に特異的なアデノウイルスベクターおよびその使用の方法 | |
| CA2461380A1 (en) | Hepatitis c virus vaccine | |
| JP2012139220A (ja) | 複製欠損アデノウイルスｔｎｆベクター | |
| JP7610338B2 (ja) | 血友病ａの遺伝子療法のための発現が上昇した組換えｆｖｉｉｉバリアントをコードするウイルスベクター | |
| WO1995026411A3 (en) | Composition and methods for creating syngeneic recombinant virus-producing cells | |
| Braciak et al. | Construction of recombinant human type 5 adenoviruses expressing rodent IL-6 genes. An approach to investigate in vivo cytokine function. | |
| JPH11503910A (ja) | アデノウイルスヘルパーウイルスシステム | |
| CA2315277A1 (en) | Pharmaceutical compositions containing the long pentraxin ptx3 | |
| WO2021042944A1 (zh) | 肌肉靶向的微环dna基因治疗 | |
| HU195619B (en) | Process for producing oral vaccines against hepatitis b virus | |
| JP2021500070A5 (enExample) | ||
| ES2300105T3 (es) | Vectores adenoviricos para terapia genica. | |
| WO2000022137A3 (en) | Selectively replicating viral vectors | |
| CN100471957C (zh) | 用于免疫治疗的腺病毒载体 | |
| JP4124565B2 (ja) | インターフェロンβのような分泌タンパク質をコードする遺伝子を使用する治療のための方法および組成物 | |
| Chengalvala et al. | Adenovirus vectors for gene expression | |
| JP2003189887A5 (enExample) | ||
| WO2023202469A1 (zh) | 一种用于遗传性凝血因子缺乏病治疗的核酸构建体及其用途 | |
| Yao et al. | Adenovirus-mediated transfer of human factor IX gene in immunodeficient and normal mice: evidence for prolonged stability and activity of the transgene in liver | |
| ES2226597T1 (es) | Vectores recombinantes virales y no virales que contienen el gen humano de urokinasa del activador del plasminogeno y su utilizacion en el tratamiento de varios tipos de fibrosis hepatica, renal, pulmonar, pancreatica y cardiaca y cicatrices hipertroficas. |